Advances in development of large animal models of liver fibrosis and cirrhosis

World Chinese Journal of Digestology

Volumn 21, Issue 5, 2013, Pages 421-426

  Guo, Ruo Han ^a   Bai, Bin ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Animal model; Experimental research; Liver cirrhosis; Liver fibrosis

Indexed keywords

DISEASE MODEL; DOG; HAPLORHINI; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; RABBIT; REVIEW; SWINE;

EID: 84922687166     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.3748/wcjd.v21.i5.421     Document Type: Review

References (50)

1. Wirkowska A, Paczek L. [Liver fibrosis and cirrhosis--causes. Part I]. Przegl Lek 2011; 68: 222-227 [PMID: 21853678]
2. Pinzani M, Rosselli M, Zuckermann M. Liver cirrhosis. Best Pract Res Clin Gastroenterol 2011; 25: 281-290 [PMID: 21497745 DOI: 10.1016/j.bpg.2011.02.009]
3. Masuda Y. [Learning toxicology from carbon tetrachloride-induced hepatotoxicity]. Yakugaku Zasshi 2006; 126: 885-899 [PMID: 17016019 DOI: 10.1248/ yakushi.126.885]
4. Knockaert L, Berson A, Ribault C, Prost PE, Fautrel A, Pajaud J, Lepage S, Lucas-Clerc C, Bégué JM, Fromenty B, Robin MA. Carbon tetrachloridemediated lipid peroxidation induces early mitochondrial alterations in mouse liver. Lab Invest 2012; 92: 396-410 [PMID: 22157718 DOI: 10.1038/labinvest. 2011.193]
5. Chinese source
6. Bravo E, D'Amore E, Ciaffoni F, Mammola CL. Evaluation of the spontaneous reversibility of carbon tetrachloride-induced liver cirrhosis in rabbits. Lab Anim 2012; 46: 122-128 [PMID: 22522417 DOI: 10.1258/la.2012.011035]
7. Chinese source
8. Osna N. Alcohol and liver disease. Semin Liver Dis 2009; 29: 139 [PMID: 19387913 DOI: 10.1055/ s-0029-1214369]
9. Chinese source
10. Chinese source
11. Crawford MA, Hassam AG. Letter: Diagnostic test for multiple sclerosis. Br Med J 1975; 1: 150-151 [PMID: 1111723 DOI: 10.1046/j.1440-1681.2000.03381.x]
12. Ugazio G, Bosia S, Cornaglia E. Experimental model of cirrhosis in rabbits exposed to carbon tetrachloride by inhalation. Res Commun Mol Pathol Pharmacol 1995; 88: 63-77 [PMID: 7620839]
13. Chen IS, Chen YC, Chou CH, Chuang RF, Sheen LY, Chiu CH. Hepatoprotection of silymarin against thioacetamide-induced chronic liver fibrosis. J Sci Food Agric 2012; 92: 1441-1447 [PMID: 22102319 DOI: 10.1002/jsfa.4723]
14. Xie Y, Wang G, Wang H, Yao X, Jiang S, Kang A, Zhou F, Xie T, Hao H. Cytochrome P450 dysregulations in thioacetamide-induced liver cirrhosis in rats and the counteracting effects of hepatoprotective agents. Drug Metab Dispos 2012; 40: 796-802 [PMID: 22266841 DOI: 10.1124/dmd.111.043539]
15. Chinese source
16. Xu H, Qian H, Zhu W, Zhang X, Yan Y, Mao F, Wang M, Xu H, Xu W. Mesenchymal stem cells relieve fibrosis of Schistosoma japonicum-induced mouse liver injury. Exp Biol Med (Maywood) 2012; 237: 585-592 [PMID: 22678013 DOI: 10.1258/ ebm.2012.011362]
17. Zou WL, Yang Z, Zang YJ, Li DJ, Liang ZP, Shen ZY. Inhibitory effects of prostaglandin E1 on activation of hepatic stellate cells in rabbits with schistosomiasis. Hepatobiliary Pancreat Dis Int 2007; 6: 176-181 [PMID: 17374578]
18. Wang P, Liang YZ. Chemical composition and inhibitory effect on hepatic fibrosis of Danggui Buxue Decoction. Fitoterapia 2010; 81: 793-798 [PMID: 20451591 DOI: 10.1016/j.fitote.2010.04.007]
19. Huang D, Chen Y, Zeng Q, Zhao J, Wu R, Wu X, Li Y. Transarterial embolization using pingyangmycin lipiodol emulsion and polyvinyl alcohol for the treatment of focal nodular hyperplasia of the liver. Hepatogastroenterology 2011; 58: 1736-1741 [PMID: 21940344 DOI: 10.5754/hge11174]
20. Chinese source
21. Chinese source
22. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152 DOI: 10.1056/NEJMra011775]
23. Ogawa T, Fujii H, Yoshizato K, Kawada N. A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits. Am J Pathol 2010; 177: 153-165 [PMID: 20489159 DOI: 10.2353/ajpath. 2010.090895]
24. Kainuma M, Fujimoto M, Sekiya N, Tsuneyama K, Cheng C, Takano Y, Terasawa K, Shimada Y. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol 2006; 41: 971-980 [PMID: 17096066 DOI: 10.1007/ s00535-006-1883-1]
25. Aguilera CM, Ramirez-Tortosa CL, Quiles JL, Yago MD, Martínez-Burgos MA, Martínez-Victoria E, Gil A, Ramirez-Tortosa MC. Monounsaturated and omega-3 but not omega-6 polyunsaturated fatty acids improve hepatic fibrosis in hypercholesterolemic rabbits. Nutrition 2005; 21: 363-371 [PMID: 15797680]
26. Fu JF, Fang YL, Liang L, Wang CL, Hong F, Dong GP. A rabbit model of pediatric nonalcoholic steatohepatitis: the role of adiponectin. World J Gastroenterol 2009; 15: 912-918 [PMID: 19248189 DOI: 10.3748/wjg.15.912]
27. Chinese source
28. Chinese source
29. Moreira PL, An YH. Animal models for therapeutic embolization. Cardiovasc Intervent Radiol 2003; 26: 100-110 [PMID: 12677466 DOI: 10.1007/s00270-003-2632-y]
30. Chinese source
31. Chinese source
32. Goldani HA, Matte US, Ramos AR, Costa TG, Winkelmann LV, Meurer L, Vieira SM, Kieling CO, Silveira TR. The role of food restriction on CCl4-induced cirrhosis model in rats. Exp Toxicol Pathol 2007; 58: 331-337 [PMID: 17275271 DOI: 10.1016/ j.etp.2006.11.007]
33. Yang ZH, Ye XH, Tan Y, Zhang M, Zhou MZ, Xie JX, Chen M, Zhou C. Evaluation of cirrhotic liver with perfusion-weighted magnetic resonance imaging: a preliminary experimental study in animal models with half-liver cirrhosis. Chin Med Sci J 2006; 21: 252-257 [PMID: 17249201]
34. Chen JY, Chen HL, Cheng JC, Lin HJ, Tung YT, Lin CF, Chen CM. A Chinese herbal medicine, Gexia-Zhuyu Tang (GZT), prevents dimethylnitrosamineinduced liver fibrosis through inhibition of hepatic stellate cells proliferation. J Ethnopharmacol 2012; 142: 811-818 [PMID: 22706148 DOI: 10.1016/ j.jep.2012.06.005]
35. Mwanza T, Miyamoto T, Okumura M, Kadosawa T, Fujinaga T. Ultrasonography, biochemical and hematological profiles in liver disease caused by intravenous administration of dimethylnitrosamine in dogs. Jpn J Vet Res 1997; 45: 153-161 [PMID: 9433016]
36. Horiguchi K, Hirano T, Ueki T, Hirakawa K, Fujimoto J. Treating liver cirrhosis in dogs with hepatocyte growth factor gene therapy via the hepatic artery. J Hepatobiliary Pancreat Surg 2009; 16: 171-177 [PMID: 19221688 DOI: 10.1007/s00534-008-0029-7]
37. Chinese source
38. Chinese source
39. Chinese source
40. Chinese source
41. Chinese source
42. Zhang JJ, Meng XK, Dong C, Qiao JL, Zhang RF, Yue GQ, Zhong HY. Development of a new animal model of liver cirrhosis in swine. Eur Surg Res 2009; 42: 35-39 [PMID: 18987472 DOI: 10.1159/000167855]
43. Chinese source
44. Chinese source
45. He XJ, Huang TZ, Wang PJ, Peng XC, Li WC, Wang J, Tang J, Feng N, Yu MH. Morphological and biomechanical remodeling of the hepatic portal vein in a swine model of portal hypertension. Ann Vasc Surg 2012; 26: 259-267 [PMID: 22192237 DOI: 10.1016/ j.avsg.2011.10.007]
46. Chinese source
47. Avritscher R, Wright KC, Javadi S, Uthamanthil R, Gupta S, Gagea M, Bassett RL, Murthy R, Wallace MJ, Madoff DC. Development of a large animal model of cirrhosis and portal hypertension using hepatic transarterial embolization: a study in swine. J Vasc Interv Radiol 2011; 22: 1329-1334 [PMID: 21802316 DOI: 10.1016/j.jvir.2011.04.016]
48. Chinese source
49. Shi LB, Peng CH, Peng SY, Liu YB, He W, Xu B, Chen XP, Bai MD, Wang Y, Tang Z. [Preliminary experimental study on treatment of portal hypertension with auxiliary partial orthotopic liver transplantation]. Zhongguo Weizhongbing Jijiu Yixue 2004; 16: 730-733 [PMID: 15585146]
50. Chinese source